# CANBESURE STUDY (Cancer, Bemiparin and Surgery Evaluation)

> **NCT00219973** · PHASE3 · COMPLETED · sponsor: **Rovi Pharmaceuticals Laboratories** · enrollment: 526 (estimated)

## Conditions studied

- Cancer
- Venous Thromboembolism

## Interventions

- **DRUG:** Bemiparin

## Key facts

- **NCT ID:** NCT00219973
- **Lead sponsor:** Rovi Pharmaceuticals Laboratories
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05
- **Primary completion:** —
- **Final completion:** 2009-04
- **Target enrollment:** 526 (ESTIMATED)
- **Last updated:** 2010-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00219973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00219973, "CANBESURE STUDY (Cancer, Bemiparin and Surgery Evaluation)". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT00219973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*